BALAXI — Balaxi Pharmaceuticals Balance Sheet
0.000.00%
- IN₹2.03bn
- IN₹2.21bn
- IN₹2.93bn
Annual balance sheet for Balaxi Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IAS | IAS | IAS | IAS | IAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 16.7 | 71.9 | 282 | 623 | 394 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 774 | 318 | 562 | 634 | 1,214 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 938 | 1,410 | 1,935 | 2,102 | 2,428 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 11.7 | 60.3 | 190 | 171 | 363 |
| Net Goodwill | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 997 | 1,765 | 2,397 | 2,583 | 3,103 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 347 | 633 | 531 | 542 | 545 |
| Long Term Debt | |||||
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 347 | 633 | 568 | 570 | 786 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 650 | 1,132 | 1,829 | 2,014 | 2,317 |
| Total Liabilities & Shareholders' Equity | 997 | 1,765 | 2,397 | 2,583 | 3,103 |
| Total Common Shares Outstanding |